UPDATE: Auriga Raises PT to $57 on JAZZ Pharmaceuticals

Auriga raises its price target on Buy-rated JAZZ Pharmaceuticals JAZZ to $57 from $55 as the company posted another consensus-beating quarter. Auriga says, "We remain impressed by Jazz's execution, as the company had another quarter of record revenue and EPS. The company also closed the Azur Pharma acquisition ahead of schedule, and we view 2012 guidance as being conservative. With its efficient tax structure and outstanding business execution, we think Jazz is well positioned to grow via M&A, a strategy used successfully by Valeant Pharmaceuticals." JAZZ closed at $50.55 a share on Monday.